SOLUBILITY AND DISSOLUTION CONSIDERATIONS FOR AMORPHOUS SOLID DISPERSIONS - Pharmaceutical Amorphous Solid Dispersions - page 258

132. Azarmi, S., Roa, W.H., and Lobenberg, R. (2008) Targeted delivery of nanoparticles for the
treatment of lung diseases. Adv. Drug Deliv. Rev. , 60(8):863-875.
133. Frenkel, Y.V., Clark, A.D., Das, K., et al. (2005) Concentration and pH dependent
aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med.
Chem. , 48(6):1974-1983.
134. Serajuddin, A.T.M. (1999) Solid dispersion of poorly water-soluble drugs: early promises,
subsequent problems, and recent breakthroughs. J. Pharm. Sci. , 88(10):1058

1066.
135. Moribe, K., Pongpeerapat, A., Tozuka, Y., and Yamamoto, K. (2006) Drug nanoparticle
formation from drug/HPMC/SDS ternary ground mixtures. Die Pharm. Int. J. Pharm. Sci. ,
61(2):97-101.
136. Dahan, A., Miller, J.M., and Amidon, G.L. (2009) Prediction of solubility and permeability
class membership: provisional BCS classification of the world's top oral drugs. AAPS J. ,
11(4):740-746.
137. Lipinski, C. (2002) Poor aqueous solubility: an industry wide problem in drug discovery. Am.
Pharm. Rev. , 5(3):82-85.
138. Fadda, H.M., McConnell, E.L., Short, M.D., and Basit, A.W. (2009) Meal induced
acceleration of tablet transit through the human small intestine. Pharm. Res. , 26(2):356-360.

-